The portuguese society of rheumatology position paper on the use of biosimilars

Acta Reumatologica Portuguesa

Volumn 39, Issue 1, 2014, Pages 60-71

  Fonseca, João Eurico ^a   Gonçalves, João ^b   Araújo, Filipe ^b   Cordeiro, Inês ^b   Teixeira, Filipa ^b   Canhão, Helena ^b   Jose Antonio Pereira da Silva ^b   Garcês, Sandra ^b   Miranda, Luís Cunha ^b   Ramiro, Sofia ^b   Roxo, Ana ^b   Pimentel Santos, Fernando M ^b   Tavares, Viviana ^b   Neto, Adriano ^b   Sepriano, Alexandre ^b   Malcata, Armando ^b   Faustino, Augusto ^b   Silva, Cândida ^b   Ambrósio, Catarina ^b   Duarte, Cátia ^b   Miguel, Cláudia ^b   Barcelos, Filipe ^b   Santos, Helena ^b   Cunha, Inês ^b   Ramos, João Carlos ^b   Gomes, José António Melo ^b   Pimentão, José Bravo ^b   Costa, Lúcia ^b   Maurício, Luís ^b   Silva, Margarida ^b   Bernardes, Miguel ^b   Bogas, Mónica ^b   Coelho, Paulo Clemente ^b   Monteiro, Paulo ^b   Aguiar, Renata ^b   André, Rui ^b   Leitão, Rui ^b   Pimenta, Sofia ^b   Meirinhos, Tiago ^b   Fernandes, Susana ^b   Las, Vera ^b   Castelão, Walter ^b   more..

^a UNIVERSITY OF LISBON   (Portugal)

^b NONE

Author keywords

Ankylosing spondylitis; Automatic substitution; Biosimilar; Extrapolation; Infliximab; Interchangeability; Position paper; Review; Rheumatoid arthritis; Switching

Indexed keywords

BIOSIMILAR AGENT;

HUMAN; PRACTICE GUIDELINE; RHEUMATIC DISEASES;

BIOSIMILAR PHARMACEUTICALS; HUMANS; RHEUMATIC DISEASES;

EID: 84897545473     PISSN: 0303464X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Biotechnology Industry Organization website. http://www. bio.org/node/517. Accessed in December 19th, 2011.
2. Volume 9A of The Rules Governing Medicinal Products in the European Union. European Medicines Agency, September 2008. http://ec.europa.eu/health/files/eudralex/vol- 9/pdf/ vol9a_09-2008_en.pdf. Accessed in August 2nd, 2012.
3. Guideline on Immunogenicity Assessment of Biotechnology- Derived Therapeutic Proteins. European Medicines Agency, 2007. http://www.ema.europa.eu/docs/en_GB/document_library/ Scientific_guideline/2009/09/ WC500003947.pdf. Accessed in July 3rd, 2012.
4. McCamish M, Woollett G. Worldwide experience with biosimilar development. MAbs 2011; 3: 209-217.
5. Schiestl M, Stangler T, Torella C, Cepeljnik T, Toll H, Grau R. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol 2011; 29: 310-312.
6. ICH harmonised tripartite guideline: comparability of biotechnological/ biological products subject to changes in their manufacturing process Q5E. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. November 2004. http://www.ich.org/ fileadmin/Public_Web_Site/ICH_Products/ Guidelines/Quality/Q5E/Step4/Q5E_Guideline.pdf. Accessed in November 2013.
7. Guideline on Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance: Non-Clinical and Clinical Issues EMEA/CHMP/BMWP/42832/2005. European Medicines Agency, February 2006. http://www.ema. europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003920.pdf. Accessed in July 26th, 2012.
8. European Medicines Agency Scientific Guidance Documents on Biosimilar Medicines. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_ 000408.jsp&murl=menus/regulations/regulations.jsp &mid=WC0b01ac058002958c&jsenabled=true. Accessed in September 4th, 2012.
9. Schellekens H, Moors E. Clinical comparability and European biosimilar regulations. Nat Biotechnol 2010; 28: 28-31.
10. Lubiniecki A, Volkin DB, Federici M, et al. Comparability assessments of process and product changes made during development of two different monoclonal antibodies. Biologicals 2011; 39: 9-22.
11. Miletich J, Eich G, Grampp G, et al. Biosimilars 2.0: Guiding principles for a global 'patients first' standard. MAbs 2011; 3: 318-325.
12. European Medicines Agency. EPAR summary for the public - Inflectra. http://www.ema.europa.eu/docs/en_GB/document_ library/EPAR_-_Summary_for_the_public/human/002778/WC500151491.pdf (accessed 11 Oct 2013).
13. European Medicines Agency. EPAR summary for the public - Remsima. http://www.ema.europa.eu/docs/en_GB/document_ library/EPAR_-_Summary_for_the_public/human/002576/WC500150872.pdf (accessed 11 Oct 2013).
14. Park W, Hrycaj P, Jeka S, et al. A randomised, double blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis Published Online First 16 May 2013. doi:10.1136/annrheumdis-2012- 203091.
15. Yoo D, Hrycaj P, Miranda P, et al. randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis Published Online First 16 May 2013. doi:10.1136/ann - rheumdis-2012-203090.
16. Committee on Rheumatologic Care. Position statement on biosimilars. American College of Rheumatology, 2010. www.rheumatology.org/practice/clinical/position/biosimilars. pdf. Accessed in September 29th, 2013.
17. Espinosa Morales R, Díaz Borjón A, Barile Fabris LA, et al. Biosimilar drugs in Mexico: position of the Mexican College of Rheumatology, 2012. Reumatol Clin 2013; 9: 113-116.
18. Position Statement on Generic Therapeutic & Biosimilar Substitution. American Academy of Dermatology and AAD Association, 2012. http://www.aad.org/Forms/Policies/Uploads/PS/PS-Therapeutic%20Substitution.pdf. Accessed in September 30th, 2013.
19. Danese S, Gomollon F; Governing Board and Operational Board of ECCO. ECCO position statement: The use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD). J Crohns Colitis. 2013;7:586-589.
20. Argüelles-Arias F, Barreiro-de-Acosta M, Carballo F, Hinojosa J, Tejerina T. Joint position statement by Spanish Society of Gastroenterology and Spanish Society of Pharmacology on biosimilar therapy for inflammatory bowel disease. Rev Esp Enferm Dig. 2013; 105: 37-43.
21. Gastl G, Geissler D, Geissler K,et al. ASHO position paper on Biosimilars. memo - Magazine of European Medical Oncology 2008; 2: 232-233.
22. Barosi G, Bosi A, Abbracchio MP, et al. Key concepts and critical issues on epoetin and filgrastim biosimilars: A position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation. Haematologica 2011; 96: 937-942.
23. Harenberg J, Kalodiki E, Walenga JM; Working Group of the IUA Scientific Committee. Ensuring safety of biosimilar low- -molecular-weight heparins: a consensus statement of the International Union of Angiology. Int Angiol 2012; 31: 101- -104.
24. Recommandations d'utilisation des biosimilaires de l'Erythropoïétine (EPO). Société Française de Néphrologie/Société Francophone de Dyalise, 2009. http://www.soc-nephrologie. org/PDF/esociete/groupes/biosimilaires.pdf. Accessed in September 29th, 2013.
25. Biosimilar substitution. National Psoriasis Foundation Medical Board website, 2013. http://www.psoriasis.org/aboutpsoriasis/treatments/statement-on-biosimilars. Accessed in September 30th, 2013.
26. NCCN Oncology Policy Summit: Biosimilars - Regulatory, Scientific, and Patient Safety Perspectives. National Comprehensive Cancer Network, 2011. http://www.nccn.org/professionals/meetings/oncology_policy_program/biosimilars. aspx. Accessed in October 1st, 2013.
27. Docket No. FDA-2010-N-0477 Approval Pathway for Biosimilar and Interchangeable Biological Products. National Haemophilia Foundation, 2010. http://www.hemophilia. org/NHFWeb/Resource/StaticPages/menu0/menu7/menu12 2/NHF_FDABiosimilars.pdf. Accessed in September 28th, 2013.
28. Position statement on biosimilar insulins. Diabetes UK, 2013. http://www.diabetes.org.uk/Documents/Position% 20statements/diabetes-uk-position-statement-biosimilar- insulins-1013.pdf. Accessed in October 1st, 2013.
29. EBE-EFPIA position paper: labelling of biosimilar medicinal products. European Biopharmaceutical Enterprises/European Federation of Pharmaceutical Industries and Associations, 2007.http://www.biofarmacos.org/files/contenido/Ebe-Efpia_Biosimilars_labelling_position_paper_28_mar_07.pdf Accessed in September 27th, 2013.
30. Background Paper by BIO Deutschland on Biosimilars. Biotechnology Industry Organization Deutschland, 2012. http://www.biodeutschland.org/tl_files/content_eng/Position% 20papers/2012/120306_FIN_Hintergrundpapier_Biosimilars% 20_ENGLISCH.pdf. Accessed in September 30th, 2013.
31. Similar biotherapeutic products: scientific and regulatory considerations. International Federation of Pharmaceutical Manufacturers and Associations, 2011. http://www.ifpma. org/fileadmin/content/Publication/2013/IFPMA_BiosimilarWEB. pdf. Accessed in September 29th, 2013.
32. OPPI position paper on biosimilars. Organisation of Pharmaceutical Producers of India, 2012. http://www.indiaoppi. com/oppibiosimilars.pdf. Accessed in September 30th, 2013.
33. Biosimilars: position paper. Belgian Biotechnology Industry Organization, Essenscia, 2013. http://www.essenscia.be/Upload/Docs/BiosimilarsBio-E.pdf. Accessed in October 1st, 2013.
34. Biosimilars: GPhA position. Generic Pharmaceutical Association, 2013. http://www.gphaonline.org/issues/biosimilars. Accessed in September 28th, 2013.
35. ABPI position on biosimilar medicines. Association of the British Pharmaceutical Industry, 2013. http://www.abpi.org. uk/_layouts/download.aspx?SourceUrl=/our-work/library/industry/Documents/ABPI%20biosimilars%20position% 20paper.pdf Accessed in September 29th, 2013.
36. Position paper: biossimilares. Apifarma, 2013. http://www. apifarma.pt/areas/biotecnologia/Documents/PostionPaper- Biossimilares_APIFARMA_Abril2013.pdf. Accessed in September 29th, 2013.
37. Biosimilars: MISG panel & forum topic proposal. Department of Health's Ministerial Industry Strategy Group, 2009. http://www.mhra.gov.uk/home/groups/es-policy/documents/websiteresources/con2030475.pdf. Accessed in September 30th, 2013.
38. Position Paper sui Farmaci Biosimilari. Agenzia Italiana del Farmaco, 2013. http://www.agenziafarmaco.gov.it/sites/de fault/files/AIFA_POSITION_PAPER_FARMACI_BIOSIMILARI. pdf. Accessed in October 1st, 2013.
39. Policy statements: biosimilar medicines. Scottish Medicines Consortium, 2011. http://www.scottishmedicines.org.uk/About_SMC/Policy_Statements/Biosimilar_Medicines. Accessed in October 2nd 2013.
40. Guidance for sponsors: information and submission requirements for subsequent entry biologics. Health Canada, 2010. http://www.hc-sc.gc.ca/dhp-mps/brgtherap/applicdemande/guides/seb-pbu/seb-pbu_2010-eng.php. Accessed in October 1st, 2013.
41. Public policy statement: biosimilars. Merck Sharp & Dohme, June 2010. http://www.merck.com/about/views-and- -positions/merck_biosimilars_public_policy2010.pdf. Accessed in September 30th, 2013.
42. Biosimilars and patient safety. Eli Lilly and Company, December 2012. Accessed in September 28th, 2013.
43. Roche: an innovator's perspective and position on biosimilars. Roche, September 2010. http://www.roche.com/irp101005.pdf. Accessed in September 29th, 2013.
44. Our Global Position Statement on Biosimilars. Brystol Meyers Squibb, 2013. http://www.bms.com/responsibility/key_issues/Pages/Biosimilars.aspx. Accessed in October 1st, 2013.